DK200101919A - Bone marrow specific protein - Google Patents
Bone marrow specific protein Download PDFInfo
- Publication number
- DK200101919A DK200101919A DK200101919A DKPA200101919A DK200101919A DK 200101919 A DK200101919 A DK 200101919A DK 200101919 A DK200101919 A DK 200101919A DK PA200101919 A DKPA200101919 A DK PA200101919A DK 200101919 A DK200101919 A DK 200101919A
- Authority
- DK
- Denmark
- Prior art keywords
- leu
- homo sapiens
- dna
- glu
- polypeptide
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title description 10
- 102000004169 proteins and genes Human genes 0.000 title description 9
- 210000001185 bone marrow Anatomy 0.000 title 1
- 241000282414 Homo sapiens Species 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108010034529 leucyl-lysine Proteins 0.000 description 4
- ZVZRQKJOQQAFCF-ULQDDVLXSA-N Lys-Tyr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZVZRQKJOQQAFCF-ULQDDVLXSA-N 0.000 description 3
- KXUZHWXENMYOHC-QEJZJMRPSA-N Phe-Leu-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O KXUZHWXENMYOHC-QEJZJMRPSA-N 0.000 description 3
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 3
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 108010003137 tyrosyltyrosine Proteins 0.000 description 3
- RBOBTTLFPRSXKZ-BZSNNMDCSA-N Asn-Phe-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RBOBTTLFPRSXKZ-BZSNNMDCSA-N 0.000 description 2
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 2
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 2
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 2
- VSRCAOIHMGCIJK-SRVKXCTJSA-N Glu-Leu-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VSRCAOIHMGCIJK-SRVKXCTJSA-N 0.000 description 2
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 2
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 2
- LNDVNHOSZQPJGI-AVGNSLFASA-N His-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNDVNHOSZQPJGI-AVGNSLFASA-N 0.000 description 2
- LEDRIAHEWDJRMF-CFMVVWHZSA-N Ile-Asn-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LEDRIAHEWDJRMF-CFMVVWHZSA-N 0.000 description 2
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 2
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 2
- GBESYURLQOYWLU-LAEOZQHASA-N Val-Glu-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GBESYURLQOYWLU-LAEOZQHASA-N 0.000 description 2
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 1
- FTSAJSADJCMDHH-CIUDSAMLSA-N Asn-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N FTSAJSADJCMDHH-CIUDSAMLSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- YFGUZQQCSDZRBN-DCAQKATOSA-N Asp-Pro-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YFGUZQQCSDZRBN-DCAQKATOSA-N 0.000 description 1
- 101100122202 Caenorhabditis elegans glod-4 gene Proteins 0.000 description 1
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- FGSGPLRPQCZBSQ-AVGNSLFASA-N Glu-Phe-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O FGSGPLRPQCZBSQ-AVGNSLFASA-N 0.000 description 1
- DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- QEVRUYFHWJJUHZ-DCAQKATOSA-N Met-Ala-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C QEVRUYFHWJJUHZ-DCAQKATOSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- LTFSLKWFMWZEBD-IMJSIDKUSA-N Ser-Asn Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O LTFSLKWFMWZEBD-IMJSIDKUSA-N 0.000 description 1
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 1
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 1
- OQCXTUQTKQFDCX-HTUGSXCWSA-N Thr-Glu-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O OQCXTUQTKQFDCX-HTUGSXCWSA-N 0.000 description 1
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- XKTWZYNTLXITCY-QRTARXTBSA-N Trp-Val-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 XKTWZYNTLXITCY-QRTARXTBSA-N 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 1
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- CLJDCQWROXMJAZ-UHFFFAOYSA-N n-[2-(4-amino-n-ethyl-3-methylanilino)ethyl]methanesulfonamide;sulfuric acid Chemical compound OS(O)(=O)=O.CS(=O)(=O)NCCN(CC)C1=CC=C(N)C(C)=C1 CLJDCQWROXMJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
SEQUENCE LISTING <110> Human Genome Sciences, Inc. <120> Bone Marrow-Specific ProteinSEQUENCE LISTING <110> Human Genome Sciences, Inc. <120> Bone Marrow-Specific Protein
<130> PF495.PCT <140> Unassigned <141> 2000-01-13 <150> 60/116,236 <151> 1999-01-15 <160> 23 <170> Patentln Ver. 2.1 <210> 1 <211> 485<130> PF495.PCT <140> Unassigned <141> 2000-01-13 <150> 60 / 116,236 <151> 1999-01-15 <160> 23 <170> Patent Vern. 2.1 <210> 1 <211> 485
<212> DNA <213> Homo sapiens <22 0> <221> CDS <222> (62)..(367) <400> 1 agattcacgc accctcaaga gtgtgggtga gacatataca gcctgttaga cctgaaggca 60 g atg get ett ett aag gcc aat aag gat etc att tcc gca gga ttg aag 109 Met Ala Leu Leu Lys Ala Asn Lys Asp Leu Ile Ser Ala Gly Leu Lys 15 10 15 gag ttc age gtt ctg ctg aat cag cag gtc ttc aat gat cct etc gtc 157<212> DNA <213> Homo sapiens <22 0> <221> CDS <222> (62) .. (367) <400> 1 agattcacgc accctcaaga gtgtgggtga gacatataca gcctgttaga cctgaaggca 60 g atg get one aag gcc aat aag hole etc to tcc gca gga ttg aag 109 Met Ala Leu Leu Lys Ala Asn Lys Asp Leu Ile Ser Ala Gly Leu Lys 15 10 15 gag ttc age gtt ctg ctg aat cag cag gtc ttc aat hole cct etc gtc 157
Glu Phe Ser Val Leu Leu Asn Gin Gin Val Phe Asn Asp Pro Leu Val 20 25 30 tet gaa gaa gac atg gtg act gtg gtg gag gac tgg atg aac ttc tac 205Glu Phe Ser Val Leu Asn Gin Gin Val Phe Asn Asp Pro Leu Val 20 25 30 tet gaa gaa gac atg gtg act gtg gtg gag gac tgg atg aac ttc tac 205
Ser Glu Glu Asp Met Val Thr Val Val Glu Asp Trp Met Asn Phe Tyr 35 40 45 ate aac tat tac agg cag cag gtg aca ggg gag ccc caa gag ega gac 253Ser Glu Glu Asp With Val Thr Val Val Glu Asp Trp With Asn Phe Tyr 35 40 45 ate aac tat tac agg cag cag gtg aca ggg gag ccc caa gag ega gac 253
Ile Asn Tyr Tyr Arg Gin Gin Val Thr Gly Glu Pro Gin Glu Arg Asp 50 55 60 aag get ctg cag gag ett egg caa gag ctg aac act ctg gcc aac cct 301Ile Asn Tyr Tyr Arg Gin Gin Val Thr Gly Glu Pro Gin Glu Arg Asp 50 55 60 aag get ctg cag gag et egg caa gag ctg aac act ctg gcc aac cct 301
Lys Ala Leu Gin Glu Leu Arg Gin Glu Leu Asn Thr Leu Ala Asn Pro 65 70 75 80 ttc ctg gcc aag tac agg gac ttc ctg aag tet cat gag etc ccg agt 349List Ala Leu Gin Glu Leu Arg Gin Glu Leu Asn Thr Leu Ala Asn Pro 65 70 75 80 ttc ctg gcc aag tac agg gac ttc ctg aag tet cat gag etc ccg agt 349
Phe Leu Ala Lys Tyr Arg Asp Phe Leu Lys Ser His Glu Leu Pro Ser 85 90 95 cac cca ccg ccc tcc tcc tagctcaggg acccagcccc tcctctctga 397Phe Leu Ala Lys Tyr Arg Asp Phe Leu Lys Ser His Glu Leu Pro Ser 85 90 95 cac cca ccg ccc tcc tcc tagctcaggg acccagcccc tcctctctga 397
His Pro Pro Pro Ser Ser 100 gaaactctga ccttcatgtc cttaggctgt gctcctgcca ctctaccctg acacctcaat 457 aaagaccagt gctggttttg ttggaaaa 485His Pro Pro Pro Ser Ser 100 gaaactctga ccttcatgtc cttaggctgt gctcctgcca ctctaccctg acacctcaat 457 aaagaccagt gctggttttg ttggaaaa 485
<210> 2 <211> 102 <212> PRT <213> Homo sapiens <400> 2<210> 2 <211> 102 <212> PRT <213> Homo sapiens <400> 2
Met Ala Leu Leu Lys Ala Asn Lys Asp Leu Ile Ser Ala Gly Leu Lys 15 10 15With Ala Leu Leu List Ala Asn List Asp Leu Ile Ser Ala Gly Leu List 15 10 15
Glu Phe Ser Val Leu Leu Asn Gin Gin Val Phe Asn Asp Pro Leu Val 20 25 30Glu Phe Ser Val Leu Asn Gin Gin Val Phe Asn Asp Pro Leu Val 20 25 30
Ser Glu Glu Asp Met Val Thr Val Val Glu Asp Trp Met Asn Phe Tyr 35 40 45Ser Glu Glu Asp With Val Thr Val Val Glu Asp Trp With Asn Phe Tyr 35 40 45
Ile Asn Tyr Tyr Arg Gin Gin Val Thr Gly Glu Pro Gin Glu Arg Asp 50 55 50Ile Asn Tyr Tyr Arg Gin Gin Val Thr Gly Glu Pro Gin Glu Arg Asp 50 55 50
Lys Ala Leu Gin Glu Leu Arg Gin Glu Leu Asn Thr Leu Ala Asn Pro 65 70 75 80List Ala Leu Gin Glu Leu Arg Gin Glu Leu Asn Thr Leu Ala Asn Pro 65 70 75 80
Phe Leu Ala Lys Tyr Arg Asp Phe Leu Lys Ser His Glu Leu Pro Ser 85 90 95Phe Leu Ala Lys Tyr Arg Asp Phe Leu Lys Ser His Glu Leu Pro Ser 85 90 95
His Pro Pro Pro Ser Ser 100His Pro Pro Pro Ser Ser 100
<210> 3 <211> 102 <212> PRT <213> Homo sapiens <400> 3<210> 3 <211> 102 <212> PRT <213> Homo sapiens <400> 3
Met Ala Pro Phe Gin Ser Asn Lys Asp Leu Ile Ser Thr Gly Ile Lys 15 10 15With Ala Pro Phe Gin Ser Asn List Asp Leu Ile Ser Thr Gly Ile List 15 10 15
Glu Phe Asn Val Leu Leu Asp Gin Gin Val Phe Asp Asp Pro Leu Ile 20 25 30Glu Phe Asn Val Leu Asp Gin Gin Val Phe Asp Asp Pro Leu Ile 20 25 30
Ser Glu Glu Asp Met Val Ile Val Val His Asp Trp Val Asn Leu Tyr 35 40 45Ser Glu Glu Asp With Val Ile Val Val His Asp Trp Val Asn Leu Tyr 35 40 45
Thr Asn Tyr Tyr Lys Lys Leu Val His Gly Glu Gin Glu Glu Gin Asp 50 55 60Thr Asn Tyr Tyr Light Light Leu Val His Gly Glu Gin Glu Glu Gin Asp 50 55 60
Arg Ala Met Thr Glu Phe Gin Gin Glu Leu Ser Thr Leu Gly Ser Gin 65 70 75 80Arg Ala With Thr Glu Phe Gin Gin Glu Leu Ser Thr Leu Gly Ser Gin 65 70 75 80
Phe Leu Ala Lys Tyr Arg Thr Phe Leu Lys Ser Lys Glu Pro Pro Ser 85 90 95Phe Leu Ala Lys Tyr Arg Thr Phe Leu Lys Ser Lys Glu Pro Pro Ser 85 90 95
Asn Thr Leu Pro Ser Ser 100 <210> 4 <211> 36Asn Thr Leu Pro Ser Ser 100 <210> 4 <211> 36
<212> DNA <213> Homo sapiens <400> 4 ctgcagccat ggctcttctt aaggccaata aggatc 36 <210> 5 <211> 37<212> DNA <213> Homo sapiens <400> 4 ctgcagccat ggctcttctt aaggccaata aggatc 36 <210> 5 <211> 37
<212> DNA <213> Homo sapiens <400> 5 tctcccaagc ttttaggagg agggcggtgg gtgactc 37<212> DNA <213> Homo sapiens <400> 5 tctcccaagc ttttaggagg agggcggtgg gtgactc 37
<210> 6 <211> 42 < 212 > DNA <213> Homo sapiens <400> 6 ctacgcggat ccgccatcat ggctcttctt aaggccaata ag 42<210> 6 <211> 42 <212> DNA <213> Homo sapiens <400> 6 ctacgcggat ccgccatcat ggctcttctt aaggccaata ag 42
<210> 7 <211> 33 <212> DNA <213> Homo sapiens <400> 7 ctctgctcta gactaggagg agggcggtgg gtg 33 <210> 8 <211> 42<210> 7 <211> 33 <212> DNA <213> Homo sapiens <400> 7 ctctgctcta gactaggagg agggcggtgg gtg 33 <210> 8 <211> 42
<212> DNA <213> Homo sapiens <400> 8 gcagcaggat ccgccatcat ggctcttctt aaggccaata ag 42<212> DNA <213> Homo sapiens <400> 8 gcagcaggat ccgccatcat ggctcttctt aaggccaata ag 42
<210> 9 <211> 30 <212> DNA <213> Homo sapiens <400> 9 gcagcaggta ccggaggagg gcggtgggtg 30<210> 9 <211> 30 <212> DNA <213> Homo sapiens <400> 9 gcagcaggta ccggaggagg gcggtgggtg 30
<210> 10 <211> 733 <212> DNA <213> Homo sapiens <400> 10 gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60 aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120 tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180 tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240 aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300 ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360 agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420 catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480 atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540 ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg 500 acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660 acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720 gactctagag gat 733 <210> 11 <211> 86 <212> DNA <213> Homo sapiens <400> 11 gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60 cccgaaatat ctgccatctc aattag 86 <210> 12 <211> 27<210> 10 <211> 733 <212> DNA <213> Homo sapiens <400> 10 gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg 60 aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120 tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg 180 tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg 240 aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact 300 ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg 360 agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc 420 catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct 480 atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga 540 ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg 500 acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc 660 acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc 720 gactctagag hole 733 <210> 11 <211> 86 <212> DNA <213> Homo sapiens <400> 11 gcgcctcgag atttccccga aatctag that tccccgaaat gatttccccg aaatgatttc 60 cccgaaatat ctgccatctc aattag 86 <210> 12 <211> 27
<212> DNA <213> Homo sapiens <400> 12 gcggcaagct ttttgcaaag cctaggc 27 <210> 13 <211> 271<212> DNA <213> Homo sapiens <400> 12 gcggcaagct ttttgcaaag cctaggc 27 <210> 13 <211> 271
<212> DNA <213> Homo sapiens <400> 13 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60 aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120 gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240 ttttggaggc ctaggctttt gcaaaaagct t 271 <210> 14 <211> 32<212> DNA <213> Homo sapiens <400> 13 ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60 aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120 gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180 ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240 ttttggaggc ctaggctttt gcaaaaagct t 271 <210> 14 <211> 32
<212> DNA <213> Homo sapiens <400> 14 gcgctcgagg gatgacagcg atagaacccc gg 32<212> DNA <213> Homo sapiens <400> 14 gcgctcgagg gatgacagcg atagaacccc gg 32
<210> 15 <211> 31 <212> DNA <213> Homo sapiens <400> 15 gcgaagcttc gcgactcccc ggatccgcct c 31<210> 15 <211> 31 <212> DNA <213> Homo sapiens <400> 15 gcgaagcttc gcgactcccc ggatccgcct c 31
<210> 16 <211> 12 <212> DNA <213> Homo sapiens <400> 16 ggggactttc cc 12<210> 16 <211> 12 <212> DNA <213> Homo sapiens <400> 16 ggggactttc cc 12
<210> 17 <211> 73 <212> DNA <213> Homo sapiens <400> 17 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60 ccatctcaat tag 73 <210> 18 <211> 27<210> 17 <211> 73 <212> DNA <213> Homo sapiens <400> 17 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60 ccatctcaat tag 73 <210> 18 <211> 27
<212> DNA <213> Homo sapiens <400> 18 gcggcaagct ttttgcaaag cctaggc 27<212> DNA <213> Homo sapiens <400> 18 gcggcaagct ttttgcaaag cctaggc 27
<210> 19 <211> 256 <212> DNA <213> Homo sapiens <400> 19 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60 caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc taactccgcc 120 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240 cttttgcaaa aagctt 256<210> 19 <211> 256 <212> DNA <213> Homo sapiens <400> 19 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60 caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc taactccgcc 120 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240 cttttgcaaa aagctt 256
<210> 20 <211> 293 <212> DNA <213> Homo sapiens <2 2 0> <221> misc_feature <222> (33) <223> n equals a, t, g or c <22 0> <221> misc_feature <222> (122) <223> n equals a, t, g or c <400> 20 tatacagcct gttagacctg aagatggctc ttnttaaggc caataaggat ctcatttccg 60 cagattgaag gagttcagcg ttctgctgaa tcagcaggtc ttcaatgatc ctttcgtctc 120 tnaagaagac atggtgactg tggtggagga ctggatgaac ttctacatca actattacag 180 gcagcaggtg acaggggagc cccaagagcg agacaaggct ctgcaggagc ttcggcaaga 240 gctgaacact ctggccaacc ctttcctggc caagtacagg gacttcctga agt 293<210> 20 <211> 293 <212> DNA <213> Homo sapiens <2 2 0> <221> misc_feature <222> (33) <223> n equals a, t, g or c <22 0> <221 > misc_feature <222> (122) <223> n equals a, t, g or c <400> 20 tatacagcct gttagacctg aagatggctc ttnttaaggc caataaggat ctcatttccg 60 cagattgaag gagttcagcg ttctgctgaa tcagcaggtc ttcaatgatc ctttcgtctc 120 tnaagaagac atggtgactg tggtggagga ctggatgaac ttctacatca actattacag 180 gcagcaggtg acaggggagc cccaagagcg agacaaggct ctgcaggagc ttcggcaaga 240 gctgaacact ctggccaacc ctttcctggc caagtacagg gacttcctga agt 293
<210> 21 <211> 272 <212> DNA <213> Homo sapiens <220> <221> misc_feature <222> (174) <223> n equals a, t, g or c <220> <221> misc_feature <222> (226) <223> n equals a, t, g or c <40O> 21 atacagcctg ttagacctga aggcagatgg ctctttttaa ggccaataag gatctcattt 60 ccgcagattg aaggagttca gcgttctgct gaatcagcag gtcttcaatg atcctctcgt 120 ctctgaagaa gacatggtga ctgtggtgga ggactggatg aacttctaca tcanctatta 180 caggcagcag gtgacagggg agccccaaga gcgagacaag gctctncagg agcttcggca 240 agagctgaac actctggcca accctttcct gg 272<210> 21 <211> 272 <212> DNA <213> Homo sapiens <220> <221> misc_feature <222> (174) <223> n equals a, t, g or c <220> <221> misc_feature < 222> (226) <223> n equals a, t, g or c <40o> 21 atacagcctg ttagacctga aggcagatgg ctctttttaa ggccaataag gatctcattt 60 ccgcagattg aaggagttca gcgttctgct gaatcagcag gtcttcaatg atcctctcgt 120 ctctgaagaa gacatggtga ctgtggtgga ggactggatg aacttctaca tcanctatta 180 caggcagcag gtgacagggg agccccaaga gcgagacaag gctctncagg agcttcggca 240 agagctgaac actctggcca accctttcct gg 272
<210> 22 <2U> 50 <212 > DNA <213> Homo sapiens <400> 22 gcagcaggat ccatggctct tcttaaggcc aataaggatc tcatttccgc 50<210> 22 <2U> 50 <212> DNA <213> Homo sapiens <400> 22 gcagcaggat ccatggctct tcttaaggcc aataaggatc tcatttccgc 50
<210> 23 <211> 36 <212> DNA <213> Homo sapiens <400> 23 gcagcatcta gaggaggagg gcggtgggtg actcgg 36<210> 23 <211> 36 <212> DNA <213> Homo sapiens <400> 23 gcagcatcta gaggaggagg gcggtgggtg actcgg 36
What Is Claimed Is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polynucleotide fragment of SEQ ID NO: 1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: 203571; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: 203571; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: 203571; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: 203571; (e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No: 203571 having biological activity; (f) a polynucleotide which is a variant of SEQ ID NO: 1; (g) a polynucleotide which is an allelic variant of SEQ ID NO: 1; (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:2; (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues. 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a mature form or a secreted protein. 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:2 or the coding sequence included in ATCC Deposit No: 203571. 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:l or the cDNA sequence included in ATCC Deposit No: 203571. 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus. 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus. 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1. 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1. 9. A recombinant host cell produced by the method of claim 9. 10. The recombinant host cell of claim 9 comprising vector sequences. 11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: 203571; (b) a polypeptide fragment of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: 203571 having biological activity; (c) a polypeptide domain of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: 203571; (d) a polypeptide epitope of SEQ ID NO:2 or the encoded sequence included in ATCC Deposit No: 203571; (e) a mature form of a secreted protein; (f) a full length secreted protein; (g) a variant of SEQ ID NO:2; (h) an allelic variant of SEQ ID NO;2; or (i) a species homologue of the SEQ ID NO:2. 12. The isolated polypeptide of claim 11, wherein the mature form or the full length secreted protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus. 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11. 14. A recombinant host cell that expresses the isolated polypeptide of claim 11. 15. A method of making an isolated polypeptide comprising: (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide. 16. The polypeptide produced by claim 15. 17. A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1. 18. A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11. 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising: (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation. 20. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising: (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide. 21. A method for identifying binding partner to the polypeptide of claim 11 comprising: (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide. 22. The gene corresponding to the cDNA sequence of SEQ ID NO:2. 23. A method of identifying an activity in a biological assay, wherein the method comprises: (a) expressing SEQ ID NO: 1 in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity. 24. The product produced by the method of claim 23.What Is Claimed Is: 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polynucleotide fragment of SEQ ID NO: 1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: 203571; (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO: 2 or the cDNA sequence included in ATCC Deposit No: 203571; (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO: 2 or the cDNA sequence included in ATCC Deposit No: 203571; (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO: 2 or the cDNA sequence included in ATCC Deposit No: 203571; (e) a polynucleotide encoding a polypeptide of SEQ ID NO: 2 or the cDNA sequence included in ATCC Deposit No: 203571 having biological activity; (f) a polynucleotide which is a variant of SEQ ID NO: 1; (g) a polynucleotide which is an allelic variant of SEQ ID NO: 1; (h) a polynucleotide which encodes a species homologue of the SEQ ID NO: 2; (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a) - (h), said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or or only T residues. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a mature form or a secreted protein. 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO: 2 or the coding sequence included in ATCC Deposit No: 203571. 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO: 1 or the cDNA sequence included in ATCC Deposit No: 203571. 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus. 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1. 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1. 9. A recombinant host cell produced by the method of claim 9. 10 The recombinant host cell of claim 9 comprising vector sequences. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) a polypeptide fragment of SEQ ID NO: 2 or the encoded sequence included in ATCC Deposit No: 203571; (b) a polypeptide fragment of SEQ ID NO: 2 or the encoded sequence included in ATCC Deposit No: 203571 having biological activity; (c) a polypeptide domain of SEQ ID NO: 2 or the encoded sequence included in ATCC Deposit No: 203571; (d) a polypeptide epitope of SEQ ID NO: 2 or the encoded sequence included in ATCC Deposit No: 203571; (e) a mature form of a secreted protein; (f) a full length secreted protein; (g) a variant of SEQ ID NO: 2; (h) in allelic variant of SEQ ID NO: 2; or (i) a species homologue of the SEQ ID NO: 2. The isolated polypeptide of claim 11, wherein the mature form or the full length secreted protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus. An isolated antibody that binds specifically to the isolated polypeptide of claim 11. 14. A recombinant host cell expressing the isolated polypeptide of claim 11. 15. A method of making an isolated polypeptide comprising: (a) culturing the recombinant host cell or claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide. 16. The polypeptide produced by claim 15. 17. A method of preventing, treating, or ameliorating a medical condition comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1. 18. A method of preventing, treating, or ameliorating a medical condition comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11. 19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising: (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising: (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample ; (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide. A method of identifying binding partner to the polypeptide of claim 11 comprising: (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide. 22. The gene corresponding to the cDNA sequence of SEQ ID NO: 2. A method of identifying an activity in a biological assay, the method comprising: (a) expressing SEQ ID NO: 1 in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity. 24. The product produced by the method of claim 23.
Figure 1Figure 1
Nucleotide and Amino Acid Sequence of BMSP 1 AGATTCACGCACCCTCAAGAGTGTGGGTGAGACATATACAGCCTGTTAGACCTGAAGGCA 60 61 GATGGCTCrrCTTAAGGCCAATAAGGATCTCAITrCCGCAGGATrGAAGGAGTTCAGCGT 120 1 MALL KANKDLIS A G L K E F S V 20Nucleotide and Amino Acid Sequence of BMSP 1
CD-I CD-II * . * 121 TCTGCTGAATCAGCAGGTCTTCAATGATCCTCTCGTCTCTGAAGAAGACATGGTGACTGT 180 21 LLNOOVFNDPLVS EEDMV T ^ 40CD-I CD-II *. * 121 TCTGCTGAATCAGCAGGTCTTCAATGATCCTCTCGTCTCTGAAGAAGACATGGTGACTGT 180 21 LLNOOVFNDPLVS EEDMV T ^ 40
CD-II CD-III 181 GGTGGAGGACTGGATGAACTTCTACATCAACTATTACAGGCAGCAGGTGACAGGGGAGCC 240 41 V E D W Μ K F Y I N. Y Y R Q Q V T G E P 60CD-II CD-III 181 GGTGGAGGACTGGATGAACTTCTACATCAACTATTACAGGCAGCAGGTGACAGGGGAGCC 240 41 V E D W Μ K F Y I N. Y Y R Q Q V T G E P 60
CD-III CD-IV CD-VCD-III CD-IV CD-V
241 CCAAGAGCGAGACAAGGCTCTGCAGGAGCTTCGGCAAGAGCTCAACACTCTGGCCAACCC 30061QE R DKALQELR0 E LNTLANP80CD-VCD-VT301TTTCCTGGCCAAGTACAGGGACTTCCTGAAGTCTCATGAGCTCCrGAGTCACCCACCGCC36081FL A KYRDFLKSΗ E LPsHPPP100CD-VII 361 CTCCTCCTAGCTCAGGGACCCAGCCCCTCCTCTCTGAGAAACTCTrGACCTTCATGTCCTT 420 101 S S 102 421 AGGCTGTGCTCCTGCCACTCTACCCTGACACCTCAATAAAGACCAGTGCTGGTTTTGTTG 480 481 GAAAA 485241 CCAAGAGCGAGACAAGGCTCTGCAGGAGCTTCGGCAAGAGCTCAACACTCTGGCCAACCC 30061QE R DKALQELR0 E-LNTLANP80CD VCD VT301TTTCCTGGCCAAGTACAGGGACTTCCTGAAGTCTCATGAGCTCCrGAGTCACCCACCGCC36081FL A KYRDFLKSΗ LPsHPPP100CD E-VII CTCCTCCTAGCTCAGGGACCCAGCCCCTCCTCTCTGAGAAACTCTrGACCTTCATGTCCTT 361 420 101 S S 102 421 480 481 AGGCTGTGCTCCTGCCACTCTACCCTGACACCTCAATAAAGACCAGTGCTGGTTTTGTTG GAAAA 485
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11623699P | 1999-01-15 | 1999-01-15 | |
| PCT/US2000/000770 WO2000042165A2 (en) | 1999-01-15 | 2000-01-13 | Bone marrow-specific protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200101919A true DK200101919A (en) | 2001-12-19 |
Family
ID=22366018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200101919A DK200101919A (en) | 1999-01-15 | 2001-12-19 | Bone marrow specific protein |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6534485B1 (en) |
| JP (1) | JP2002534112A (en) |
| AU (1) | AU2964700A (en) |
| CA (1) | CA2359132A1 (en) |
| DK (1) | DK200101919A (en) |
| GB (1) | GB0130539D0 (en) |
| WO (1) | WO2000042165A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1130030A1 (en) * | 2000-03-02 | 2001-09-05 | Roche Diagnostics Corporation | Human erythroid differentiation related factor |
| GB0026604D0 (en) | 2000-10-31 | 2000-12-13 | Roslin Inst Edinburgh | Diagnostic method |
| JP2005168360A (en) * | 2003-12-09 | 2005-06-30 | Olympus Corp | Method for examining biological tissue-supplying material, device, cell culture container and method for examining culturing state |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0941366A2 (en) * | 1996-11-06 | 1999-09-15 | Whitehead Institute For Biomedical Research | Biallelic markers |
| WO2001019860A2 (en) | 1999-09-15 | 2001-03-22 | Incyte Genomics, Inc. | Proteins associated with cell differentiation |
| AU2001243142A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2001057190A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
-
2000
- 2000-01-13 JP JP2000593722A patent/JP2002534112A/en not_active Withdrawn
- 2000-01-13 CA CA002359132A patent/CA2359132A1/en not_active Abandoned
- 2000-01-13 AU AU29647/00A patent/AU2964700A/en not_active Abandoned
- 2000-01-13 US US09/482,271 patent/US6534485B1/en not_active Expired - Fee Related
- 2000-01-13 WO PCT/US2000/000770 patent/WO2000042165A2/en not_active Ceased
-
2001
- 2001-12-19 DK DK200101919A patent/DK200101919A/en unknown
- 2001-12-20 GB GBGB0130539.0A patent/GB0130539D0/en active Pending
-
2003
- 2003-01-14 US US10/341,344 patent/US20030191062A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2964700A (en) | 2000-08-01 |
| JP2002534112A (en) | 2002-10-15 |
| CA2359132A1 (en) | 2000-07-20 |
| GB0130539D0 (en) | 2002-02-06 |
| US20030191062A1 (en) | 2003-10-09 |
| WO2000042165A3 (en) | 2001-05-31 |
| WO2000042165A2 (en) | 2000-07-20 |
| US6534485B1 (en) | 2003-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2366130A1 (en) | Human cancer associated gene sequences and polypeptides | |
| US6509173B1 (en) | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2 | |
| US6448230B1 (en) | Testis expressed polypeptide | |
| US20030180892A1 (en) | Interleukin-20 | |
| CA2302808C (en) | 50 human secreted proteins | |
| CA2520097C (en) | Truncated baff receptors | |
| CA2323776C (en) | Cytokine receptor common gamma chain like | |
| US6531447B1 (en) | Secreted protein HEMCM42 | |
| EP0974058A2 (en) | 20 human secreted proteins | |
| US20030045459A1 (en) | 67 Human secreted proteins | |
| US20040002066A1 (en) | 36 human secreted proteins | |
| US20030069405A1 (en) | 70 human secreted proteins | |
| CA2319644A1 (en) | Human serine protease and serpin polypeptides | |
| US20040024192A1 (en) | 19 human secreted proteins | |
| DK200101919A (en) | Bone marrow specific protein | |
| US6433139B1 (en) | Secreted protein HPEAD48 | |
| US6806351B2 (en) | Secreted protein HBJFE12 | |
| US20040197345A1 (en) | Prostate derived Ets factor | |
| US20040038275A1 (en) | Human frezzled-like protein | |
| US6410709B1 (en) | Cornichon-like protein | |
| US20030144492A1 (en) | 101 human secreted proteins | |
| US20040014110A1 (en) | Dendritic enriched secreted lymphocyte activation molecule | |
| US20020058307A1 (en) | 20 Human secreted proteins | |
| US6365369B1 (en) | Prostate specific secreted protein | |
| US20030211578A1 (en) | Interferon receptor HKAEF92 |